Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bayer, CRISPR form gene editing JV to cure blood disorders, blindness, and congenital heart disease

Executive Summary

Bayer HealthCare Pharmaceuticals AG and CRISPR Therapeutics formed a 50/50 joint venture tasked with finding cures for blood disorders (including hemophilia), blindness, and congenital heart disease. The Bayer LifeScience Center (BLSC), a new R&D innovation unit at Bayer, help set up the JV, which will focus on creating delivery systems for systemic administration of CRISPR-Cas9 technology.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Joint Venture
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies